Kodiak Sciences Inc (KOD) Stock Price, Quote & News

Company Profile

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degenerati...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 281 0850

Website: kodiak.com

Address:

1200 Page Mill Road, Palo Alto, United States

Cutlass Nov. 14 at 10:49 PM

$KOD Monday Monday 🎶🎵🎼👀

0 · Reply

ZacksResearch Nov. 14 at 12:37 PM

$KOD reports wider Q3 loss — still holding strong? The loss of $1.16 per share missed the Zacks Consensus Estimate, with R&D spend increasing due to clinical and manufacturing activities, now down to $72M in cash reserves. Yet, shares have surged 89.1% YTD, outpacing the industry’s 15.4% growth. Full analysis on KOD's pipeline and prospects here 👉 https://www.zacks.com/stock/news/2791044/kodiak-q3-loss-wider-than-expected-pipeline-development-in-focus?cid=sm-stocktwits-2-2791044-body-21080&ADID=SYND_STOCKTWITS_TWEET_2_2791044_BODY_21080

0 · Reply

ZacksResearch Nov. 14 at 12:37 PM

0 · Reply

ZacksResearch Nov. 14 at 11:37 AM

Q3 pain for $KOD… but is this the setup before the big data hits? The company posted a wider Q3 loss as rising R&D spend pushes its eye-disease pipeline forward ahead of key data readouts — that’s the real story here. Full breakdown here 👉 https://www.zacks.com/stock/news/2791044/kodiak-q3-loss-wider-than-expected-pipeline-development-in-focus?cid=sm-stocktwits-2-2791044-teaser-21021&ADID=SYND_STOCKTWITS_TWEET_2_2791044_TEASER_21021

0 · Reply

d_risk Nov. 13 at 9:55 PM

$KOD - Kodiak Sciences Inc Common Stock - 10Q - Updated Risk Factors KOD’s 10-Q risk factors for 2025 spotlight resumed tarcocimab development amid FDA concerns, expanded R&D and regulatory hurdles, intense competition, manufacturing and supply chain complexities, new legal and policy uncertainties post-Loper Bright, heightened IP and patent litigation risks, and detailed exposure to pricing, reimbursement, and commercialization challenges. #Biotechnology #SupplyChainChallenges #IPLitigation #RegulatoryRisk #PharmaceuticalR&D 🟢 Added 🟠 Removed https://d-risk.ai/KOD/10-Q/2025-11-13

0 · Reply

Cutlass Nov. 12 at 10:50 PM

$KOD PALO ALTO, Calif. , Nov. 12, 2025 /PRNewswire/ -- Kodiak Sciences Inc.(KOD) , a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today that Victor Perlroth, M.D., Chief Executive Officer, will present at the following upcoming investor conferences: Jefferies Global Healthcare Conference in London, UK Date: Monday, November 17, 2025 Time: 4:30pm GMT (8:30am PST) Format: Presentation 8th Annual Evercore Healthcare Conference in Coral Gables, Florida Date: Wednesday, December 3, 2025 Time: 3:00pm EST (12pm PST) Format: Fireside chat

0 · Reply

Cutlass Nov. 12 at 8:37 PM

$KOD Good week going here - 👀

0 · Reply

Stekli27 Nov. 11 at 9:52 PM

$KOD 👀 very

0 · Reply

Cutlass Nov. 11 at 3:50 PM

$KOD Perky today ✔️

0 · Reply

jdlman Nov. 11 at 2:51 PM

$KOD up 4% .wow

0 · Reply

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results

Nov 12, 2025, 5:48 PM EST - 3 days ago

Kodiak Sciences to Present at Upcoming Investor Conferences

Nov 5, 2025, 7:00 AM EST - 10 days ago

Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI)

Oct 31, 2025, 12:01 PM EDT - 15 days ago

The Big 3: GOOGL, KOD, FTK

GOOG GOOGL FTK

Sep 15, 2025, 7:00 AM EDT - 2 months ago

New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)

Sep 2, 2025, 8:00 AM EDT - 2 months ago

Kodiak Sciences to Participate in Upcoming Scientific Conferences Highlighting KSI-101 in Patients with Macular Edema Secondary to Inflammation (MESI)

Aug 27, 2025, 10:40 AM EDT - 2 months ago

Harbour BioMed Reports 2025 Interim Results

Aug 27, 2025, 6:54 AM EDT - 2 months ago

Jim Cramer: Kodiak Sciences Is A 'Pure Spec' Stock, Recommends Buying This Utilities Stock

Aug 19, 2025, 2:18 PM EDT - 3 months ago

Kodiak Sciences to Present at American Chemical Society Fall 2025

Aug 13, 2025, 4:00 PM EDT - 3 months ago

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results

Jul 10, 2025, 8:00 AM EDT - 4 months ago

Kodiak Sciences to Host Investor R&D Day on July 16, 2025

Jun 25, 2025, 4:45 PM EDT - 5 months ago

Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society

May 29, 2025, 9:32 PM EDT - 6 months ago

Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference

May 14, 2025, 4:15 PM EDT - 6 months ago

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results

May 1, 2025, 11:43 PM EDT - 7 months ago

Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases

Mar 27, 2025, 4:01 PM EDT - 8 months ago

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Mar 10, 2025, 4:39 PM EDT - 8 months ago

Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy

Feb 23, 2025, 8:08 PM EST - 9 months ago

Kodiak Sciences: Anti-VEGF Could Win Nicely On Retinal Disorders

Feb 4, 2025, 7:30 AM EST - 10 months ago

Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025

Jan 7, 2025, 6:00 AM EST - 11 months ago

Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 9, 2024, 12:33 PM EST - 1 year ago

Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock

Nov 14, 2024, 4:01 PM EST - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Nov 11, 2024, 6:15 AM EST - 1 year ago

Kodiak Sciences to Participate in Upcoming Investor Conferences

Oct 14, 2024, 5:35 PM EDT - 1 year ago

Kodiak Sciences to Present at Innovate Retina 2024

Sep 23, 2024, 6:00 AM EDT - 1 year ago

Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time

Sep 17, 2024, 4:05 PM EDT - 1 year ago

Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City

Aug 14, 2024, 4:01 PM EDT - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results

May 29, 2024, 4:36 PM EDT - 1 year ago

Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences

May 15, 2024, 4:01 PM EDT - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results

May 13, 2024, 7:32 PM EDT - 1 year ago

Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy

May 2, 2024, 4:30 PM EDT - 1 year ago

Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform

Mar 28, 2024, 8:57 PM EDT - 1 year ago

Kodiak Sciences Inc. (KOD) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 6:30 AM EDT - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Mar 26, 2024, 6:15 AM EDT - 1 year ago

Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024

Jan 30, 2024, 6:30 AM EST - 1 year ago

Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting

Jan 4, 2024, 4:15 PM EST - 2 years ago

Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 21, 2023, 4:15 PM EST - 2 years ago

Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference

Nov 14, 2023, 4:01 PM EST - 2 years ago

Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 6, 2023, 5:00 AM EST - 2 years ago

Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission

Nov 1, 2023, 11:21 PM EDT - 2 years ago

KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING

Oct 11, 2023, 6:00 AM EDT - 2 years ago

Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society

Sep 8, 2023, 6:00 AM EDT - 2 years ago

Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Sep 7, 2023, 6:00 AM EDT - 2 years ago

New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion

Aug 14, 2023, 4:01 PM EDT - 2 years ago

Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights

Jul 24, 2023, 6:38 AM EDT - 2 years ago

Kodiak Sciences scraps development of eye disorder drug

Jul 24, 2023, 6:36 AM EDT - 2 years ago

Kodiak Sciences stock plunges into record-low territory after decision to discontinue wet AMD treatment

Jul 24, 2023, 6:00 AM EDT - 2 years ago

Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program

May 15, 2023, 4:01 PM EDT - 2 years ago

Kodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business Highlights

Apr 21, 2023, 7:30 AM EDT - 2 years ago

Kodiak Sciences Announces Upcoming Presentations on its Product and Research Pipeline at ARVO 2023 Annual Meeting

Cutlass Nov. 14 at 10:49 PM

$KOD Monday Monday 🎶🎵🎼👀

0 · Reply

ZacksResearch Nov. 14 at 12:37 PM

0 · Reply

ZacksResearch Nov. 14 at 12:37 PM

0 · Reply

ZacksResearch Nov. 14 at 11:37 AM

0 · Reply

d_risk Nov. 13 at 9:55 PM

0 · Reply

Cutlass Nov. 12 at 10:50 PM

0 · Reply

Cutlass Nov. 12 at 8:37 PM

$KOD Good week going here - 👀

0 · Reply

Stekli27 Nov. 11 at 9:52 PM

$KOD 👀 very

0 · Reply

Cutlass Nov. 11 at 3:50 PM

$KOD Perky today ✔️

0 · Reply

jdlman Nov. 11 at 2:51 PM

$KOD up 4% .wow

0 · Reply

JarvisFlow Nov. 11 at 12:37 PM

HC Wainwright & Co. has updated their rating for Kodiak Sciences ( $KOD ) to Buy with a price target of 24.

0 · Reply

Stekli27 Nov. 10 at 5:57 PM

$KOD bullish week?

1 · Reply

Stekli27 Nov. 8 at 12:16 PM

$KOD confirmed that PEAK and PINNACLE Phase 3 trials for KSI-101 are actively enrolling. Week 20 data show ≥90 % dryness and ≥15 letter gains which is among the strongest results seen in MESI. Week 24 data will be presented on February 7 2026 by Dr Sumit Sharma at Cleveland Clinic’s Angiogenesis Conference. This means KOD now has two Phase 3 assets and a clear path to two commercial markets – DME/nAMD and MESI. The company is now beyond “hope mode” and in full execution phase. Happy to see next year 100+$ Is this a new $REGN ? 😋

0 · Reply

OpenOutcrier Nov. 5 at 2:07 PM

$KOD (+2.2% pre) Kodiak reports positive 20-week data for macular edema treatment KSI-101 https://ooc.bz/l/83281

0 · Reply

Cutlass Nov. 5 at 12:16 PM

$KOD Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI) PR NEWSWIRE 6:00 AM ET 11/5/2025 🤠

0 · Reply

Nibbler Nov. 1 at 5:43 AM

$KOD I need to know.

1 · Reply

Goosey71 Oct. 31 at 7:16 PM

$KOD What happened here today? Why did it shit the bed? No dilution filings, no insider sales? Competitor news? Random something else?

2 · Reply

FE123 Oct. 31 at 12:34 PM

$KOD $PRAX Steve Cohen loves $TENX the Next $PRAX

0 · Reply

FE123 Oct. 30 at 11:46 PM

$KOD $PRAX $TENX Steve Cohen loves Blue Horse Shoe!

0 · Reply

Stekli27 Oct. 30 at 6:33 PM

$KOD I said, the BLA is getting closer. The Ursus facility at Lonza is now fully qualified and ready to start supplying product to patients. Just give us the BLA submission date, and we’ll skyrocket this thing again 🚀 And with ksi-101 phase 3 start and successfull study data? Ufffff, I bet that I know what to do with such profit 💰

1 · Reply

Cutlass Oct. 30 at 6:30 PM

$KOD Very nice 🎶

1 · Reply

isaacwilliams33 Oct. 30 at 5:56 PM

$KOD k

0 · Reply

Market Cap	1.03B
Revenue (ttm)	0.00
Net Income (ttm)	-176.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	684,200
Avg Vol	952,344
Day's Range	N/A - N/A
Shares Out	52.82M
Stochastic %K	74%
Beta	2.88
Analysts	Sell
Price Target	$20.43